retatrutide phase 3 2025 triple agonist glp-1 gip glucagon First data, a Triumph of Science! Dr. - First-in-Class 'Triple-G'! Retatrutide,

SGLT2 inhibitors provide substantial benefits for people with type 2 diabetes mellitus and either established HF or elevated HF risk [86]

Most notable is a study of cardiovascular outcomes among 2,287 patients with type 2 diabetes and obesity who underwent bariatric surgery at Cleveland Clinic and 11,435 matched controls ( JAMA

Abstract Glucagon-like peptide-1 medicines are being prescribed to growing numbers of patients worldwide, for type 2 diabetes, obesity and associated comorbidities, including cardiovascular disease, peripheral artery disease and obstructive sleep apnea, and are revolutionizing public health strategies for these conditions

According to Basilico, the effect GLP-1 drugs have on patients' appetites means there needs to be added emphasis on nutrition

H.GroenA

Romera I, Cebrian-Cuenca A, Alvarez-Guisasola F, Gomez-Peralta F, Reviriego J